Search

Omeros Corp

Closed

SectorHealthcare

18.04 -0.28

Overview

Share price change

24h

Current

Min

17.21

Max

18.14

Key metrics

By Trading Economics

Income

-38M

13M

Sales

19M

29M

P/E

Sector Avg

14.385

68.089

EPS

0.02

Profit margin

46.381

Employees

175

EBITDA

-43M

14M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+58.96% upside

Dividends

By Acuity

Next Earnings

16 lis 2026

Market Stats

By TradingEconomics

Market Cap

287M

1.3B

Previous open

18.32

Previous close

18.04

Omeros Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

9 lis 2026, 21:07 UTC

Omeros Corporation shares are advancing, recovering from an early dip and reflecting a cumulative gain since Friday's close amid a recent downward trend.

6 lis 2026, 20:46 UTC

Omeros Corporation shares are lower, retracing from an early gain, amid broader market weakness and three consecutive sessions of losses.

5 lis 2026, 21:04 UTC

Omeros Corporation shares fell sharply, reaching their lowest point around midday and remaining well below the 20-day moving average.

2 lis 2026, 21:09 UTC

Omeros Corporation shares fell significantly, reaching their lowest point in early afternoon trading amid notable volatility and remaining within the one-month trading range.

30 paź 2026, 21:21 UTC

Shares down notably in after-market trading after volatile session.

29 paź 2026, 20:02 UTC

Omeros Corporation shares are advancing, reflecting strong trading activity with high volume, despite a slight pullback from earlier session highs.

28 paź 2026, 20:52 UTC

Omeros Corporation shares are trading lower in after-market hours, reflecting a significant decline in the broader market and falling to their lowest level of the day.

27 paź 2026, 22:56 UTC

Omeros Corporation's shares traded lower in after-market hours, remaining below their 20-day moving average despite a slight recovery from an earlier decline.

23 paź 2026, 19:36 UTC

Omeros Corp shares are declining, pulling back significantly from an earlier session high and remaining below Thursday's close.

22 paź 2026, 22:41 UTC

Omeros Corp is trading lower in after-market hours, continuing a downward trend and remaining significantly below Thursday's close and its 20-day moving average.

19 paź 2026, 20:07 UTC

Event

Omeros Corp shares advanced after the CHMP issued a negative opinion on its narsoplimab marketing authorization application for thrombotic microangiopathy.

16 paź 2026, 23:51 UTC

Event

Omeros Corp receives a negative opinion from the European Medicines Agency on its narsoplimab marketing authorization application for thrombotic microangiopathy.

15 paź 2026, 19:31 UTC

Omeros Corp shares are advancing amid a broader Pharmaceuticals sector rally, with unusually high trading volume reflecting increased investor activity.

13 paź 2026, 20:08 UTC

Omeros Corp shares are declining, reaching their lowest point just before the close amid a broader market trend of significant downward movement.

6 paź 2026, 20:07 UTC

Omeros Corp shares are declining, reaching their lowest point mid-morning and finishing well below the 20-day moving average amid weaker overall market performance.

5 paź 2026, 20:06 UTC

Omeros Corp is advancing, reflecting a gain from Friday's close, despite pulling back from an earlier session high.

2 paź 2026, 21:01 UTC

Omeros Corp is trading lower in after-market hours, continuing a downward trend that has lasted for six consecutive sessions.

1 paź 2026, 22:15 UTC

Omeros Corp is trading modestly higher in after-market hours following five consecutive sessions of declines, despite mixed signals in the broader market.

30 wrz 2026, 19:46 UTC

Omeros Corp shares fell modestly Wednesday, continuing a decline observed over the past three trading days, despite remaining above the 20-day moving average.

28 wrz 2026, 20:07 UTC

Omeros Corp shares are declining, following a broader market trend, after peaking early in the session and reaching a low before the close.

24 wrz 2026, 19:35 UTC

Omeros Corp shares fell sharply after an earlier gain, despite remaining above the 20-day moving average and near the upper end of its one-month range.

23 wrz 2026, 23:02 UTC

Omeros Corp's stock declined in after-market trading, dropping from Wednesday's close despite remaining above its 20-day moving average.

22 wrz 2026, 20:02 UTC

News
Social Media

Omeros shares advance sharply after Cantor Fitzgerald upgraded the stock to Overweight, citing strong Yartemlea launch and reinstating a $22 price target.

21 wrz 2026, 19:16 UTC

Omeros Corp has advanced during Monday's trading session, reaching a notable peak earlier in the day while remaining below its 20-day moving average.

18 wrz 2026, 20:13 UTC

Omeros Corp's shares declined in after-market trading, remaining significantly below its 20-day moving average and near the lower end of its one-month range.

17 wrz 2026, 20:08 UTC

Omeros Corp is advancing sharply in Thursday's trading, having risen as much as 7% earlier before pulling back slightly, reflecting strong overall market gains.

16 wrz 2026, 19:36 UTC

Omeros Corp is trading higher, having peaked earlier in the day, though it remains below its 20-day moving average amid a broader trend of lower closes.

15 wrz 2026, 20:51 UTC

Omeros Corp shares are lower in after-market hours, continuing a five-session decline amid broader market pressures and elevated crude oil prices.

14 wrz 2026, 23:06 UTC

Omeros Corp shares are lower in after-market hours, continuing a trend of declines amid broader market pressure from rising crude oil prices.

10 wrz 2026, 20:03 UTC

Omeros Corp shares are lower today, continuing a decline since Wednesday. Trading volume is notably high, reflecting increased investor activity.

Peer Comparison

Price change

Omeros Corp Forecast

Price Target

By TipRanks

58.96% upside

12 Months Forecast

Average 27.5 USD  58.96%

High 33 USD

Low 22 USD

Based on 3 Wall Street analysts offering 12 month price targets forOmeros Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

3 ratings

2

Buy

1

Hold

0

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Omeros Corp

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
help-icon Live chat